Altogether, these results suggest that TGF-βRII silencing alters expression of MRP3 and MRP4 ABC transporters in PC cells and induces a partial EMT phenotype that could promote chemoresistance to gemcitabine. The gene discussed is ABCC4; the disease is pachyonychia congenita.